BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

468 related articles for article (PubMed ID: 25344886)

  • 1. Implications for dosimetric changes when introducing MR-guided brachytherapy for small volume cervix cancer: a comparison of CT and MR-based treatments in a single centre.
    Dempsey C; Govindarajulu G; Sridharan S; Capp A; O'Brien P
    Australas Phys Eng Sci Med; 2014 Dec; 37(4):705-12. PubMed ID: 25344886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of computed tomography and magnetic resonance imaging in cervical cancer brachytherapy target and normal tissue contouring.
    Eskander RN; Scanderbeg D; Saenz CC; Brown M; Yashar C
    Int J Gynecol Cancer; 2010 Jan; 20(1):47-53. PubMed ID: 20130502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of CT-based volumetric dosimetry with traditional prescription points in the treatment of cervical cancer with PDR brachytherapy.
    Lowrey N; Nilsson S; Moutrie Z; Chan P; Cheuk R
    J Med Imaging Radiat Oncol; 2015 Oct; 59(5):640-5. PubMed ID: 26223554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Point A vs. HR-CTV D
    Harmon G; Diak A; Shea SM; Yacoub JH; Small W; Harkenrider MM
    Brachytherapy; 2016; 15(6):825-831. PubMed ID: 27693173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 45 or 50 Gy, Which is the Optimal Radiotherapy Pelvic Dose in Locally Advanced Cervical Cancer in the Perspective of Reaching Magnetic Resonance Image-guided Adaptive Brachytherapy Planning Aims?
    Mazeron R; Petit C; Rivin E; Limkin E; Dumas I; Maroun P; Annede P; Martinetti F; Seisen T; Lefkopoulos D; Chargari C; Haie-Meder C
    Clin Oncol (R Coll Radiol); 2016 Mar; 28(3):171-7. PubMed ID: 26547694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recommendations from gynaecological (GYN) GEC ESTRO working group (II): concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy-3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology.
    Pötter R; Haie-Meder C; Van Limbergen E; Barillot I; De Brabandere M; Dimopoulos J; Dumas I; Erickson B; Lang S; Nulens A; Petrow P; Rownd J; Kirisits C;
    Radiother Oncol; 2006 Jan; 78(1):67-77. PubMed ID: 16403584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long term experience with 3D image guided brachytherapy and clinical outcome in cervical cancer patients.
    Ribeiro I; Janssen H; De Brabandere M; Nulens A; De Bal D; Vergote I; Van Limbergen E
    Radiother Oncol; 2016 Sep; 120(3):447-454. PubMed ID: 27157510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dynamics of High Risk Clinical Target Volume reduction during Brachytherapy and impact on its coverage in patients with inoperable cervical cancer.
    Pobijakova M; Scepanovic D; Paluga M; Fekete M; Mardiak J
    Neoplasma; 2018 Mar; 65(3):425-430. PubMed ID: 29788726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Practically achievable maximum high-risk clinical target volume doses in MRI-guided intracavitary brachytherapy for cervical cancer: a planning study.
    Menon G; Huang F; Sloboda R; Pearcey R; Ghosh S
    Brachytherapy; 2014; 13(6):572-8. PubMed ID: 25085455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CT-guided intracavitary radiotherapy for cervical cancer: Comparison of conventional point A plan with clinical target volume-based three-dimensional plan using dose-volume parameters.
    Shin KH; Kim TH; Cho JK; Kim JY; Park SY; Park SY; Kim DY; Chie EK; Pyo HR; Cho KH
    Int J Radiat Oncol Biol Phys; 2006 Jan; 64(1):197-204. PubMed ID: 16169676
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-risk CTV delineation for cervix brachytherapy: Application of GEC-ESTRO guidelines in Australia and New Zealand.
    Vinod SK; Lim K; Bell L; Veera J; Ohanessian L; Juresic E; Borok N; Chan P; Chee R; Do V; Govindarajulu G; Sridharan S; Johnson C; Moses D; Van Dyk S; Holloway L
    J Med Imaging Radiat Oncol; 2017 Feb; 61(1):133-140. PubMed ID: 27527506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Local recurrences in cervical cancer patients in the setting of image-guided brachytherapy: a comparison of spatial dose distribution within a matched-pair analysis.
    Schmid MP; Kirisits C; Nesvacil N; Dimopoulos JC; Berger D; Pötter R
    Radiother Oncol; 2011 Sep; 100(3):468-72. PubMed ID: 21924510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Image and laparoscopic guided interstitial brachytherapy for locally advanced primary or recurrent gynaecological cancer using the adaptive GEC ESTRO target concept.
    Fokdal L; Tanderup K; Nielsen SK; Christensen HK; Røhl L; Pedersen EM; Schønemann NK; Lindegaard JC
    Radiother Oncol; 2011 Sep; 100(3):473-9. PubMed ID: 21924784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apparent diffusion coefficients in GEC ESTRO target volumes for image guided adaptive brachytherapy of locally advanced cervical cancer.
    Haack S; Pedersen EM; Jespersen SN; Kallehauge JF; Lindegaard JC; Tanderup K
    Acta Oncol; 2010 Oct; 49(7):978-83. PubMed ID: 20831485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. From point A to the sculpted pear: MR image guidance significantly improves tumour dose and sparing of organs at risk in brachytherapy of cervical cancer.
    Tanderup K; Nielsen SK; Nyvang GB; Pedersen EM; Røhl L; Aagaard T; Fokdal L; Lindegaard JC
    Radiother Oncol; 2010 Feb; 94(2):173-80. PubMed ID: 20138380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of computed tomography with magnetic resonance imaging for imaging-based clinical target volume contours in cervical cancer brachytherapy.
    Zolciak-Siwinska A; Kowalczyk A; Sikorska K; Bijok M; Michalski W; Gruszczynska E
    Brachytherapy; 2018; 17(4):667-672. PubMed ID: 29764769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Image-guided intracavitary high-dose-rate brachytherapy for cervix cancer: A single institutional experience with three-dimensional CT-based planning.
    Wang B; Kwon A; Zhu Y; Yeo I; Henson CF
    Brachytherapy; 2009; 8(2):240-247. PubMed ID: 19230789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor and normal tissue dosimetry changes during MR-guided pulsed-dose-rate (PDR) brachytherapy for cervical cancer.
    Morgia M; Cuartero J; Walsh L; Jezioranski J; Keeler K; Xie J; Massey C; Williamson D; Cho YB; Oh S; Fyles A; Milosevic M
    Radiother Oncol; 2013 Apr; 107(1):46-51. PubMed ID: 23540555
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A dose-volume analysis of magnetic resonance imaging-aided high-dose-rate image-based interstitial brachytherapy for uterine cervical cancer.
    Yoshida K; Yamazaki H; Takenaka T; Kotsuma T; Yoshida M; Furuya S; Tanaka E; Uegaki T; Kuriyama K; Matsumoto H; Yamada S; Ban C
    Int J Radiat Oncol Biol Phys; 2010 Jul; 77(3):765-72. PubMed ID: 19836165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The dosimetric impact of heterogeneity corrections in high-dose-rate ¹⁹²Ir brachytherapy for cervical cancer: Investigation of both conventional Point-A and volume-optimized plans.
    Hyer DE; Sheybani A; Jacobson GM; Kim Y
    Brachytherapy; 2012; 11(6):515-20. PubMed ID: 22386723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.